A long-term human trial has found that a discontinued drug halved the presentation of early-onset Alzheimer's disease in ...
The recall has been issued for some products due to higher than acceptable levels of benzene, a chemical linked to leukemia and other blood disorders.
An experimental drug appears to reduce the risk of Alzheimer's-related dementia in people destined to develop the disease in their 30s, 40s or 50s, according to the results of a new study. The ...
The FDA wants to end bulk production of copycat versions of weight loss drugs; telehealth companies and compounding ...
Clinical Trials Arena on MSN21h
Roche’s discontinued Alzheimer’s drug shows signs of preventing onsetInvestigators said that the OLE study showed Roche’s gantenerumab dropped the risk of developing symptoms by 50%.
The FDA said testing of certain acne products with benzoyl peroxide found elevated levels of benzene, a chemical linked to cancer.
Roche’s up to $1 billion investment will provide access to Oxford BioTherapeutics’ antibody-drug conjugate platform for ...
We recently published a list of 10 Best Diabetes Stocks To Buy According to Billionaires. In this article, we are going to ...
Swiss drugmaker Roche has abandoned global diverse workforce targets and compatriot Novartis is ending its use of diverse ...
Roche, which put billions on the line a year ago across several ADC pacts, kicked off 2025 by returning to Innovent Biologics ...
The explosion of GLP-1 weight loss drugs is reminiscent of the early days of PD-1 inhibitors, but key market differences ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback